دورية أكاديمية
أعرض في EDS

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.

التفاصيل البيبلوغرافية
العنوان: Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.
المؤلفون: Morgenlander WR; Institute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Henson SN; Institute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Monaco DR; Institute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Chen A; Department of Biostatistics, and., Littlefield K; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Bloch EM; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Fujimura E; Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, and Department of Genetics, Program in Virology, Harvard Medical School, Boston, Massachusetts, USA., Ruczinski I; Department of Biostatistics, and., Crowley AR; Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA., Natarajan H; Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA., Butler SE; Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA., Weiner JA; Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA., Li MZ; Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, and Department of Genetics, Program in Virology, Harvard Medical School, Boston, Massachusetts, USA., Bonny TS; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Benner SE; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Balagopal A; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Sullivan D; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Shoham S; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Quinn TC; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA., Eshleman SH; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Casadevall A; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Redd AD; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA., Laeyendecker O; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA., Ackerman ME; Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA., Pekosz A; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA., Elledge SJ; Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, and Department of Genetics, Program in Virology, Harvard Medical School, Boston, Massachusetts, USA., Robinson M; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Tobian AA; Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Larman HB; Institute for Cell Engineering, Division of Immunology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
المصدر: The Journal of clinical investigation [J Clin Invest] 2021 Apr 01; Vol. 131 (7).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Antibodies, Viral/*blood , COVID-19/*immunology , COVID-19/*therapy , COVID-19/*virology , Coronavirus/*immunology , SARS-CoV-2/*immunology, Antibodies, Neutralizing/blood ; Antibody Specificity ; Coronavirus/classification ; Coronavirus/genetics ; Cross Reactions ; Endemic Diseases ; Genome, Viral ; Humans ; Immunization, Passive ; Immunodominant Epitopes/chemistry ; Immunodominant Epitopes/genetics ; Immunodominant Epitopes/immunology ; Models, Molecular ; Pandemics ; SARS-CoV-2/genetics ; Species Specificity ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; COVID-19 Serotherapy
مستخلص: SARS-CoV-2 (CoV2) antibody therapies, including COVID-19 convalescent plasma (CCP), monoclonal antibodies, and hyperimmune globulin, are among the leading treatments for individuals with early COVID-19 infection. The functionality of convalescent plasma varies greatly, but the association of antibody epitope specificities with plasma functionality remains uncharacterized. We assessed antibody functionality and reactivities to peptides across the CoV2 and the 4 endemic human coronavirus (HCoV) genomes in 126 CCP donations. We found strong correlation between plasma functionality and polyclonal antibody targeting of CoV2 spike protein peptides. Antibody reactivity to many HCoV spike peptides also displayed strong correlation with plasma functionality, including pan-coronavirus cross-reactive epitopes located in a conserved region of the fusion peptide. After accounting for antibody cross-reactivity, we identified an association between greater alphacoronavirus NL63 antibody responses and development of highly neutralizing antibodies against CoV2. We also found that plasma preferentially reactive to the CoV2 spike receptor binding domain (RBD), versus the betacoronavirus HKU1 RBD, had higher neutralizing titer. Finally, we developed a 2-peptide serosignature that identifies plasma donations with high anti-spike titer, but that suffer from low neutralizing activity. These results suggest that analysis of coronavirus antibody fine specificities may be useful for selecting desired therapeutics and understanding the complex immune responses elicited by CoV2 infection.
التعليقات: Update of: medRxiv. 2020 Dec 18;:. (PMID: 33354688)
References: J Virol. 2007 Jan;81(2):718-31. (PMID: 17079322)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
Trends Immunol. 2018 Jan;39(1):70-79. (PMID: 28867526)
Cell. 2021 Apr 1;184(7):1858-1864.e10. (PMID: 33631096)
Cell Rep Med. 2020 Oct 20;1(7):100123. (PMID: 32995758)
N Engl J Med. 2021 Feb 18;384(7):610-618. (PMID: 33406353)
Cell Rep Med. 2020 Jun 23;1(3):100040. (PMID: 32835303)
J Clin Invest. 2020 Jun 1;130(6):2757-2765. (PMID: 32254064)
Science. 2020 Dec 11;370(6522):1339-1343. (PMID: 33159009)
J Clin Invest. 2021 Jan 4;131(1):. (PMID: 32997649)
J Clin Microbiol. 2021 Jan 21;59(2):. (PMID: 33139419)
J Clin Invest. 2020 Oct 1;130(10):5235-5244. (PMID: 32634129)
Immunity. 2020 Nov 17;53(5):1095-1107.e3. (PMID: 33128877)
Nat Protoc. 2018 Sep;13(9):1958-1978. (PMID: 30190553)
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003. (PMID: 32165541)
N Engl J Med. 2021 Mar 18;384(11):1015-1027. (PMID: 33523609)
Science. 2020 Nov 27;370(6520):. (PMID: 32994364)
J Infect Dis. 2020 Nov 13;222(12):1974-1984. (PMID: 32910175)
JAMA. 2020 Jul 14;324(2):131-132. (PMID: 32539093)
Science. 2020 Aug 21;369(6506):1014-1018. (PMID: 32540904)
Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169)
J Infect Dis. 2021 Jan 4;223(1):56-61. (PMID: 33128369)
AIDS. 2016 Jan 2;30(1):113-20. (PMID: 26731757)
Virology. 2008 Oct 25;380(2):312-21. (PMID: 18760437)
J Clin Invest. 2020 Nov 2;130(11):6141-6150. (PMID: 32764200)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318)
Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337)
Transfus Apher Sci. 2021 Feb;60(1):102957. (PMID: 32972861)
معلومات مُعتمدة: R01 AI152078 United States AI NIAID NIH HHS; T32 GM136577 United States GM NIGMS NIH HHS; R01 AI120938 United States AI NIAID NIH HHS; U24 AI118633 United States AI NIAID NIH HHS; R01 AI052733 United States AI NIAID NIH HHS; R01 AI128779 United States AI NIAID NIH HHS; R01 NR005228 United States NR NINR NIH HHS; UM1 AI068613 United States AI NIAID NIH HHS; HHSN272201400007C United States AI NIAID NIH HHS; R01 GM136724 United States GM NIGMS NIH HHS; R01 HL059842 United States HL NHLBI NIH HHS; K23 HL151826 United States HL NHLBI NIH HHS; T32 AI007363 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Adaptive immunity; Immunology; Infectious disease
المشرفين على المادة: 0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (Immunodominant Epitopes)
0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
تواريخ الأحداث: Date Created: 20210211 Date Completed: 20210415 Latest Revision: 20221207
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8011893
DOI: 10.1172/JCI146927
PMID: 33571169
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI146927